Clinical Trial Update: Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update on safety and clinical outcomes in young children with Hunter syndrome treated with idursulfase.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome
• Mucopolysaccharidosis Ii

Drugs mentioned

• Idursulfase (idursulfase)

Snippet

Sponsor: Shire | Conditions: Hunter Syndrome, Mucopolysaccharidosis II | Phase 4 | Status: COMPLETED | Results posted: 2013-11-07